Gilead Sciences Inc Oncology Deep Dive Transcript
Good morning or good afternoon to you all, and thank you for joining us for our Gilead Oncology Deep Dive. We're looking forward to spending some time with you today discussing our oncology portfolio, focusing on our pipeline, which is addressing a broad range of solid tumors and heme malignant disease. Our presenters today are Daniel O'Day, Gilead's Chairman and Chief Executive Officer; Bill Grossman, our SVP and Head of our Oncology Therapeutic Area, Janet Dorling, our SVP of Global Commercial Product Strategy; See Phan, VP and Head of our Oncology Franchise for Breast; Bilal Piperdi, our VP of Oncology Clinical Development; Giri Ramsingh, Executive Director and Group Development Leader for Heme; Frank Neumann, our SVP and Global Head of Clinical Development for Kite; Bernard Fine, VP and Head of our Oncology Franchise, Early Development; and Jackson Egen, our VP of Research.
We have roughly 2 hours of prepared materials, after which we'll host an open Q&A session where you'll be able to ask a question live or submit a question through the Q
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
